



CERTIFICATE OF ANALYSIS

Page 1 of 2

Product Description: V-PLEX® SARS-CoV-2 Panel 25 Kit
Kit Catalog Numbers: K15583-Series; K15584-Series; K15585-Series; K15586-Series; K15587-Series; K15588-Series; K15589-Series
Kit Lot Number: K0081968
Expiration Date: 31 JUL 2023

Kit Components:

Description	Lot Number	Storage Temperature	Expiration Date
SARS-CoV-2 Plate 25	Z0057116	2-8°C	31 JUL 2024
Reference Standard 1	A0080286	≤ -70°C	28 FEB 2026
Serology Control 1.1	A00C0771	≤ -70°C	28 FEB 2026
Serology Control 1.2	A00C0772	≤ -70°C	28 FEB 2026
Serology Control 1.3	A00C0773	≤ -70°C	28 FEB 2026
SULFO-TAG™ Human ACE2 Protein	D0081708	2-8°C	31 JUL 2023
SULFO-TAG™ Anti-Human IgG Antibody	D00V0019	2-8°C	30 APR 2025
SULFO-TAG™ Anti-Human IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Human IgA Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgG Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgA Antibody	Not Kit Specific	2-8°C	See Label
Diluent 100	Not Kit Specific	2-8°C	See Label
MSD Blocker A Kit	Not Kit Specific	Room Temperature	See Label
MSD GOLD Read Buffer B	Not Kit Specific	Room Temperature	See Label

See product insert regarding which components are provided with each IgG, IgA, IgM, or ACE2 kit.

Plate Uniformity Testing Results:

Parameter	Precision			Uniformity	Signal
	CV of Intra-plate Averages	Average Intra-plate CV	Max Intra-plate CV	Average Uniformity Metric	Average Signal
SARS-CoV-2 Spike	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.1.529; BA.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BA.2)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.617.2; AY.4) Alt Seq 2	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BA.3)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BA.1+R346K)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BA.1+L452R)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.1.7)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.351)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.640.2)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000



CERTIFICATE OF ANALYSIS

Page 2 of 2

Coating Confirmation Testing Results:

Spot	Description	Result
1	SARS-CoV-2 Spike	Pass
2	SARS-CoV-2 Spike (B.1.1.529; BA.1)	Pass
3	SARS-CoV-2 Spike (BA.2)	Pass
4	SARS-CoV-2 Spike (B.1.617.2; AY.4) Alt Seq 2	Pass
5	SARS-CoV-2 Spike (BA.3)	Pass
6	SARS-CoV-2 Spike (BA.1+R346K)	N/A
7	SARS-CoV-2 Spike (BA.1+L452R)	N/A
8	SARS-CoV-2 Spike (B.1.1.7)	Pass
9	SARS-CoV-2 Spike (B.1.351)	Pass
10	SARS-CoV-2 Spike (B.1.640.2)	Pass

Note: Alternative S-GENE mutations for Spike of AY.1, AY.2, and B.1.617.2 are listed as “**Alt Seq#.**”

Functional Testing Results:

Sample Type	Calibrator	Controls		Samples	
Metric	Avg Signal Ratio Test:Reference	Control Recovery	Control Conc. CV	Avg % Difference Test:Reference	Slope Test:Reference
SARS-CoV-2 Spike	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.1.529; BA.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (BA.2)	N/A	N/A	N/A	N/A	N/A
SARS-CoV-2 Spike (B.1.617.2; AY.4) Alt Seq 2	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (BA.3)	N/A	N/A	N/A	N/A	N/A
SARS-CoV-2 Spike (BA.1+R346K)	N/A	N/A	N/A	N/A	N/A
SARS-CoV-2 Spike (BA.1+L452R)	N/A	N/A	N/A	N/A	N/A
SARS-CoV-2 Spike (B.1.1.7)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.351)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.640.2)	N/A	N/A	N/A	N/A	N/A

Additional Comments:

Functional testing was executed using SARS-CoV-2 Plate 25 (Z0057116), SULFO-TAG Anti-Human IgG Antibody (D00V0019), Reference Standard 1 (A0080286), and Serology Controls (A00C0771, A00C0772, A00C0773).

All kit components were manufactured and tested according to MSD documents. The lots listed in the Kit Components table meet MSD’s specifications.

Statement:

The above product is intended for Research Use Only. Not for use in Diagnostic Procedures.

	Name	Function	Signature	Date
Review/Approval	Karen Hamilla	Quality		22 FEB 2022